Table 1.
Overview of calculated IS hospitalization rates recorded before and after the introduction of annotated rotavirus vaccinations into different immunization programs. All data are derived from Retrospective Analysis Studies
| IS incidence |
IS hospitalization |
|||||||
|---|---|---|---|---|---|---|---|---|
| {Pre-vaccination era} |
{Post-vaccination era} |
{Pre-vaccination era} |
{Post-vaccination era} |
|||||
| Country | Vaccine | Age | Cases per 100,000 | IRR (95% CI) | Cases per 100,000 | Cases per 100,000 | RR (95% CI) | Reference |
| US | Rotashield | <12 m | NR | NR | 45.0–31* | 31* | NR | Simonsen et al., 200122 |
| US | HBRV | 6–14 w | NR | NR | 10.2 | 12.0–15.8 | 1.18 (0.92–1.54) – 1.55 (1.22–1.57) | Yen et al., 201223 |
| 15–24 w | NR | NR | 39.9 | 34.7–42.1 | 0.87 (0.75–1.00) – 1.05 (0.92–1.20) | |||
| US | HRV/HBRV | 6–14 w | NR | NR | 15.0 (12.6–17.8) | 17.0–22.5 | 1.13 (0.90–1.43) – 1.50 (1.22–1.83) | Tate et al., 20165 |
| 15–24 w | NR | NR | 46.4 (38.2–50.8) | 41.8–55 | 0.90 (0.79–1.03) – 1.18 (1.05–1.34) | |||
| Canada | HRV/HBRV | <12 m | 23.4 (21.5–25.4) | 0.96 (0.78–1.18) | ~20.0–27.5 | ~22.5–30 | NR | Hawken et al., 201724 |
| Taiwan | HRV/HBRV | 6–14 w | 77.0 (for <12 m) | NR | 26.2 (20.0–34.4) | 22.5 (17.1–29.6) | 0.86 (0.58–1.26) | Yen et al., 201725 |
| 15–24 w | NR | NR | 79.8 (68.8–92.5) | 66.3 (57.0–77.2) | 0.83 (0.67–1.03) | |||
| Korea | HRV/HBRV | <12 m | 234.1 | 0.66–0.81b | NR | NR | NR | Cho et al., 201826 |
| 8–11wa | 66.6 | 0.29–0.76 | NR | NR | NR | |||
| 6–14wa | NR | 0.44 (0.35–0.55) | NR | NR | NR | |||
| 15–24wa | NR | 0.60 (0.53–0.67) | NR | NR | NR | |||
IS, intussusception; IRR, incidence rate ratio; RR, rate ratio; 95% CI, 95% confidence interval; HRV, monovalent human rotavirus vaccine (Rotarix); HBRV, pentavalent bovine rotavirus vaccine (Rotateq); Age, age at which children were vaccinated; m, months; w, weeks; NR, not reported; a, calculated annual incidence rate; b, data for the entire post-vaccination era; * Rate calculated per 100,000 infant years. For the study citing Rotashield data, post-vaccination era data are reported only for the year 1998–1999, when Rotashield was available in the United States.